Ketamine - Beckley Psytech
Alternative Names: ELE-Ket+Latest Information Update: 28 Jan 2024
Price :
$50 *
At a glance
- Originator Eleusis
- Developer Beckley Psytech
- Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Mood stabilisers; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
- Mechanism of Action AMPA receptor agonists; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for clinical-Phase-Unknown development in Major depressive disorder(Adjunctive treatment) in United Kingdom
- 24 Oct 2022 Eleusis has been acquired and merged into Beckley Psytech
- 15 Dec 2020 Clinical trials in Major depressive disorder (Adjunctive treatment) in United Kingdom (unspecified route) before December 2020